- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 25.02. | 'Fear and uncertainty': Biotech investors warn of impact from NIH research cuts | ||
| 25.02. | FDA brings back some fired device office staff | ||
| 24.02. | Mirum drug for rare genetic disease gains FDA approval | ||
| 24.02. | Summit partners with Pfizer to study bispecific, ADC combinations | ||
| 24.02. | Pfizer names Patrizia Cavazzoni, former top FDA official, as chief medical officer | ||
| 24.02. | Sanofi, Teva add to case for new bowel disease drug | ||
| 24.02. | Partnering for success in early phase clinical development | ||
| 21.02. | Ozempic, Wegovy shortage resolved; Pfizer CEO is PhRMA's new chair | ||
| 21.02. | Pfizer stops selling hemophilia gene therapy, citing weak demand | ||
| 21.02. | Bluebird, at risk of default, agrees to take-private deal | ||
| 20.02. | CDC vaccine meeting, set to be first since RFK Jr. sworn in, is postponed | ||
| 20.02. | Device industry scrambles amid concern FDA layoffs will cause delays | ||
| 20.02. | In FDA job cuts, experts see threat of far-reaching impact | ||
| 20.02. | FTC case against PBMs can move forward, judge rules | ||
| 20.02. | AstraZeneca deepens China presence with FibroGen deal | ||
| 20.02. | BridgeBio's heart drug launch gets off to a fast start | ||
| 19.02. | Advamed CEO warns FDA job cuts put patients, industry at risk | ||
| 19.02. | Sanofi reaches consumer health deal; Supernus antidepressant fails study | ||
| 19.02. | FTC retains stricter merger guidelines under Trump | ||
| 19.02. | Recursion CEO launches pre-seed fund in response to NIH cuts | ||
| 18.02. | Biogen buys rights to Stoke's rare epilepsy drug | ||
| 18.02. | Solid says early data suggest 'differentiated' Duchenne gene therapy | ||
| 18.02. | GSK's 5-in-1 meningococcal shot wins FDA approval | ||
| 18.02. | Beyond copays: Redefining assistance for those with rare diseases and chronic conditions | ||
| 14.02. | 'It's not for the faint of heart.' How 3 CEOs took their biotechs public |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
